Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206492 · ClinicalTrials.gov registry record · Phase 2
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00206492 is a Phase 2 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 3 participants.
The verdict
NCT00206492, a Phase 2 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The researchers want to learn whether ZD1839 can improve the activity of tamoxifen, a drug that participants will receive for the treatment of the type of breast cancer being studied. Tamoxifen medicine is part of the standard treatment for the type of breast cancer being studied. It is approved for the treatment of this problem. In order to help the researchers understand how the cancer responds to these medicines, the researchers will take a small tissue sample (biopsy) of the breast cancer before beginning treatment and after two weeks of treatment, at 6 weeks and when surgery is done as part of treatment for the cancer. If participants do not respond to treatment, another biopsy will be done to see why the participants did not respond. These samples will also be collected to look at different characteristics of the cancer. The researchers cannot and do not guarantee that participants will benefit if they take part in this study
Interventions
- DRUG Tamoxifen
- DRUG Iressa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206492
The ClinicalTrials.gov registry entry for NCT00206492 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT00206492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206492 about?
NCT00206492 is a clinical study titled "Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients". The researchers want to learn whether ZD1839 can improve the activity of tamoxifen, a drug that participants will receive for the treatment of the type of breast cancer being studied. Tamoxifen medicine is part of the standard treatment for the type of breast cancer being studied. It is approved for...
What is the current status of trial NCT00206492?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2003-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00206492?
The interventions under investigation include: Tamoxifen (DRUG), Iressa (DRUG).
Who is sponsoring clinical trial NCT00206492?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.